Entities / Company
Protagonist Therapeutics (United States).
company in Milpitas, United States
- Reports this week
- 0
- Active events
- 0
- Connections
- 32
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
Tango Therapeutics and Protagonist Therapeutics are companies that operate within the medical and genetics industry sector.Speculative1 report
-
Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting.Some support2 reports2 developments inside
-
Protagonist Therapeutics announced positive Phase 3 results for its peptide therapeutic Rusfertide for treating Polycythemia Vera.Speculative1 report
-
Dinesh V. Patel was appointed President and CEO of Protagonist Therapeutics on July 1, 2025.Speculative1 report
-
Protagonist Therapeutics' new drug targets the same mechanism as an existing development.Speculative1 report
-
Protagonist Therapeutics belongs to the biomedical and genetics industry sector.Some support1 report
-
Protagonist Therapeutics received sizable payments from Johnson & Johnson for product milestones.Some support3 reports
No events began in the chosen period. Widen it, or reset.
Around Protagonist Therapeutics (United States) this week
News at the entities that move Protagonist Therapeutics (United States) most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Protagonist Therapeutics (United States)
-
Johnson & Johnson StructuralP&G, Johnson & Johnson, and Coca-Cola are noted as dividend growth stocks, coinciding with SEC requirements for fiduciaries to prioritize interests.Moves Protagonist Therapeutics (United States)
-
Janssen Biotech TransactionalJ&J and Janssen Biotech jointly won summary judgment in a Virginia court regarding J&J's acquisition, with FTC filing an amicus brief.Moves Protagonist Therapeutics (United States)
Connections
The 3 strongest of 32, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Janssen Biotech Transactional
Protagonist Therapeutics licensed the drug Icotrokinra to Janssen Biotech following joint discovery and collaboration.
-
FDA Structural
Protagonist Therapeutics is formally seeking and submitting New Drug Applications (NDA) to the FDA for regulatory review.
-
Johnson & Johnson Structural
Protagonist Therapeutics and Johnson & Johnson maintain a strategic partnership involving the joint development and licensing of the drug Icotrokinra.
History
Events by the month they beganJune 2026
8 events- Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.
- Tango Therapeutics and Protagonist Therapeutics are companies that operate within the medical and genetics industry sector.
- Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting.
- Protagonist Therapeutics announced positive Phase 3 results for its peptide therapeutic Rusfertide for treating Polycythemia Vera.
- Dinesh V. Patel was appointed President and CEO of Protagonist Therapeutics on July 1, 2025.
- Protagonist Therapeutics' new drug targets the same mechanism as an existing development.
- Protagonist Therapeutics belongs to the biomedical and genetics industry sector.
- Protagonist Therapeutics received sizable payments from Johnson & Johnson for product milestones.